219 related articles for article (PubMed ID: 34806858)
1. Clinical management of cUTI, cIAI, and HABP/VABP attributable to carbapenem-resistant Gram-negative infections in Spain.
Ferrer R; Fariñas MC; Maseda E; Salavert M; Bou G; Díaz-Regañón J; López D; Lozano V; Gómez-Ulloa D; Fenoll R; Lara N; McCann E
Rev Esp Quimioter; 2021 Dec; 34(6):639-650. PubMed ID: 34806858
[TBL] [Abstract][Full Text] [Related]
2. Complicated carbapenem-resistant infections: a treatment pathway analysis in Italian sites.
Durante-Mangoni E; Bertolino L; Mastroianni C; Viale P; Bassetti M; Citton R; Gómez-Ulloa D; Roset M; McCann E
Infez Med; 2021; 29(3):434-449. PubMed ID: 35146349
[TBL] [Abstract][Full Text] [Related]
3. Risk of relapse and readmission among hospitalized adults with carbapenem non-susceptible gram-negative infections.
Dillon R; Burton T; Anderson AJ; Seare J; Puzniak L
Curr Med Res Opin; 2023 Jun; 39(6):881-888. PubMed ID: 37178145
[TBL] [Abstract][Full Text] [Related]
4. Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections.
Lodise TP; Bonine NG; Ye JM; Folse HJ; Gillard P
BMC Infect Dis; 2019 Aug; 19(1):718. PubMed ID: 31412809
[TBL] [Abstract][Full Text] [Related]
5. Determining the burden of infectious diseases caused by carbapenem-resistant gram-negative bacteria in Spain.
Cantón R; Huarte R; Morata L; Trillo-Mata JL; Muñoz R; González J; Tort M; Badia X
Enferm Infecc Microbiol Clin (Engl Ed); 2021 Apr; 39(4):179-183. PubMed ID: 32576392
[TBL] [Abstract][Full Text] [Related]
6. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
Pang F; Jia XQ; Zhao QG; Zhang Y
Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291
[TBL] [Abstract][Full Text] [Related]
7. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
[TBL] [Abstract][Full Text] [Related]
8. Use of hospital resources in ICU inpatients with infections caused by carbapenem-resistant Gram-negative bacteria: A real clinical practice-based study in Spain.
Ferrer R; Garnacho-Montero J; Rascado P; Contreras S; Cantón-Bulnes L; Barral P; Del Cerro I; Badia X
Enferm Infecc Microbiol Clin (Engl Ed); 2023 Mar; 41(3):162-168. PubMed ID: 36610832
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic consumption versus the prevalence of carbapenem-resistant Gram-negative bacteria at a tertiary hospital in China from 2011 to 2017.
Zhang D; Hu S; Sun J; Zhang L; Dong H; Feng W; Lei J; Dong Y
J Infect Public Health; 2019; 12(2):195-199. PubMed ID: 30385238
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors and Molecular Epidemiology of Complicated Intra-Abdominal Infections With Carbapenem-Resistant Enterobacteriaceae: A Multicenter Study in China.
Liu J; Zhang L; Pan J; Huang M; Li Y; Zhang H; Wang R; Zhao M; Li B; Liu L; Gong Y; Bian J; Li X; Tang Y; Lei M; Chen D
J Infect Dis; 2020 Mar; 221(Suppl 2):S156-S163. PubMed ID: 32176797
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections.
Gomila A; Shaw E; Carratalà J; Leibovici L; Tebé C; Wiegand I; Vallejo-Torres L; Vigo JM; Morris S; Stoddart M; Grier S; Vank C; Cuperus N; Van den Heuvel L; Eliakim-Raz N; Vuong C; MacGowan A; Addy I; Pujol M;
Antimicrob Resist Infect Control; 2018; 7():111. PubMed ID: 30220999
[TBL] [Abstract][Full Text] [Related]
12. Bloodstream infections in children caused by carbapenem-resistant versus carbapenem-susceptible gram-negative microorganisms: Risk factors and outcome.
Ozsurekci Y; Aykac K; Cengiz AB; Basaranoglu ST; Sancak B; Karahan S; Kara A; Ceyhan M
Diagn Microbiol Infect Dis; 2017 Apr; 87(4):359-364. PubMed ID: 28089138
[TBL] [Abstract][Full Text] [Related]
13. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Popejoy MW; Long J; Huntington JA
BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
[TBL] [Abstract][Full Text] [Related]
14. Investigation and analysis of carbapenem-resistant gram-negative bacterial infection rates across hospitals in Shandong Province in China.
Liu K; Xu H; Sun J; Liu Y; Li W
Front Public Health; 2022; 10():1014995. PubMed ID: 36420011
[TBL] [Abstract][Full Text] [Related]
15. Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options.
Golan Y
BMC Infect Dis; 2015 Aug; 15():313. PubMed ID: 26243291
[TBL] [Abstract][Full Text] [Related]
16. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
17. Monitoring the antimicrobial susceptibility of Gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017).
Cantón R; Loza E; Aznar J; Castillo FJ; Cercenado E; Fraile-Ribot PA; González-Romo F; López-Hontangas JL; Rodríguez-Lozano J; Suárez-Barrenechea AI; Tubau F; Díaz-Regañón J; López-Mendoza D;
Rev Esp Quimioter; 2019 Apr; 32(2):145-155. PubMed ID: 30761824
[TBL] [Abstract][Full Text] [Related]
18. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
Mansour H; Ouweini AEL; Chahine EB; Karaoui LR
Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649
[TBL] [Abstract][Full Text] [Related]
19. High excess costs of infections caused by carbapenem-resistant Gram-negative bacilli in an endemic region.
Vargas-Alzate CA; Higuita-Gutiérrez LF; López-López L; Cienfuegos-Gallet AV; Jiménez Quiceno JN
Int J Antimicrob Agents; 2018 Apr; 51(4):601-607. PubMed ID: 29277527
[TBL] [Abstract][Full Text] [Related]
20. The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012-2019.
Zilberberg MD; Nathanson BH; Puzniak LA; Dillon RJ; Shorr AF
BMC Infect Dis; 2022 Oct; 22(1):775. PubMed ID: 36199012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
